Targets › GRN
4 programs from 4 companies in 4 trials: 4 Phase 1; Neurology; next expected readout Apr 2027.
Secreted protein that acts as a key regulator of lysosomal function and as a growth factor involved in inflammation, wound healing and cell proliferation. Regulates protein trafficking to lysosomes, and also the activity of lysosomal enzymes. (UniProt, P28799)
Open in Phaseline: the race on GRN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AviadoBio | AVB-101 AAV9-delivered GRN gene therapy | GRN | Phase 1 | Frontotemporal Dementia | Apr 2027 |
| Voyager Therapeutics | VY1706 AAV9-delivered progranulin (GRN) gene therapy | GRN | Phase 1 | Alzheimer s Disease | Apr 2029 |
| Prevail Therapeutics | LY3884963 Gene therapy delivering PGRN (progranulin) to increase progranulin protein levels | GRN | Phase 1 | Frontotemporal Dementia | Nov 2029 |
| Passage Bio | PBFT02 Gene therapy delivering functional GRN gene to the brain | GRN | Phase 1 | Frontotemporal Dementia | – |
Frontotemporal Dementia (3) Alzheimer s Disease (1)
small molecule (2), mixed (1), other (1)
Prevail Therapeutics (1) AviadoBio (1) Voyager Therapeutics (1) Passage Bio (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.